Dr. Maricich is a licensed, board-certified physician, investor, clinical developer, and strategist. He works to improve patient health and our healthcare system by investing in, advising, and providing leadership at innovative firms. At Pear Therapeutics, he leads the Clinical, Regulatory, and Quality groups as the Chief Medical Officer and Head of Development. He leads and manages the development programs from Discovery/TPP stage, through Translational, Clinical Development, Regulatory submission, and review as well as Medical Affairs. In addition to overseeing subsequent pipeline programs across a broad-spectrum of disease areas, he has led the reSET, reSET-O, and Somryst programs. Prior to joining Pear, Dr. Maricich worked with and lead successful teams and programs at Healthcare & Life Science/biotech (HLS) firms, including Corixa (acquired by GlaxoSmithKline), Xdynia (acquired by Cavion), Cavion (acquired by Jazz Pharmaceuticals) and AWS. He founded a digital health firm while a med student that used AI and NLP to structure clinical data. Dr. Maricich completed his education and training at Harvard University, the University of Washington, the University of Notre Dame, and the University of Virginia.